CareLit Fachartikel
Treatment of RRMS patients with the PPARgamma agonist actos: results of a phase I trial
C Kaiser, D Shukla, G Stebbins, D Skias, G Katsamakis, D Stefoski, D Jeffrey, D Feinstein · Aktuelle Neurologie · 2007 · Heft 09
Dokument
1106486
CareLit-ID
Jahr
2007
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Previous studies have shown that an agonist of the peroxisome proliferator activated receptor gamma (PPARg) that is currently used to treat type 2 diabetes, also shows anti-inflammatory effects in T-cells and glial cells; improves glial metabolism; and is neuroprotective. In mouse models of multiple sclerosis, PPARg agonists were shown to reduce disease severity, and in a case report the agonist Actos (pioglitazone) was shown to be well tolerated in a secondary progressive MS patient. In view of its good safety profile, we carried out a one-year, double-blinded, placebo-controlled trial of Actos (30mg daily, p.o…
Schlagworte
Actos
Atrophy
Cytokine
America
Avonex
Aktuelle Neurologie
